Author:
Ueno N T,Rizzo J D,Demirer T,Cheng Y C,Hegenbart U,Zhang M-J,Bregni M,Carella A,Blaise D,Bashey A,Bitran J D,Bolwell B J,Elfenbein G J,Fields K K,Freytes C O,Gale R P,Lazarus H M,Champlin R E,Stiff P J,Niederwieser D
Publisher
Springer Science and Business Media LLC
Subject
Transplantation,Hematology
Reference37 articles.
1. Hryniuk W, Bush H . The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984; 2: 1281–1288.
2. Hryniuk WM, Levine MN, Levin L . Analysis of dose intensity for chemotherapy in early (stage II) and advanced breast cancer. Natl Cancer Inst Monogr 1986; 1: 87–94.
3. Peters WP, Jones RB, Vredenburgh J, Shpall EJ, Hussein A, Elkordy M et al. A large prospective randomized trial of high dose combination alkylating agents (CPB) with sutologous cellular support as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (AFM). Proc Am Soc Clin Oncol 1996; 15: 121.
4. Lotz JP, Cure H, Janvier M, Morvan F, Legros M, Asselain B et al. Intensive chemotherapy and autograft of hematopoietic stem cells in the treatment of metastatic cancer: results of the national protocol Pegase 04. Hematol Cell Ther 1999; 41: 71–74.
5. Madan B, Broadwater G, Rubin P, Edwards J, Long G, Chao NC et al. Improved survival with consolidation high dose cyclophosphamide, cisplatin and carmustine compared with observation in women with metastatic breast cancer and only bone metastases treated with induction adriamycin, 5-fluorouracil and methotrexate: a phase III prospective randomized comparative trial. Proc Am Soc Clin Oncol 2000; 19: 48a.
Cited by
39 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献